The Non-penny Pot Stock Index had another down week with 22 of the 29 constituents going DOWN of which 17 did so in excess of 5% with the remaining 7 going UP of which only 1 did so in excess of 5%. In total, the index went DOWN 6.2% week-ending June 26th. The details are as follows:
By Lorimer Wilson, editor/publisher of munKNEE.com – A financial site for sore eyes and inquisitive minds
1 constituent went UP by 5% or more, namely:
- Greenlane (GNLN) +10.7%
7 constituents went DOWN by 10% or more, namely:
- XPhyto (XPHYF) -19.5%; Charlotte’s Web (CWBHF) -18.0%; Medicine Man (SHWZ) -15.2%; New Age (NBEV) -14.7%; Organigram (OGI) -11.6%; Avicanna (AVCNF) -7.5%; Innovative Industrial REIT (IIPR) -6.7%
10 constituents went DOWN between 5% and 9.9%, namely:
- Village Farms (VFF) -9.2%; Aphria (APHA) -8.3%; Canopy Growth (CGC) -8.0%; Planet 13 (PLNHF) -8.0%; cbdMD (YCBD) -7.9%; GW Pharma (GWPH) -7.3%; TerrAscend (TRSSF) -7.0%; Aurora (ACB) – 6.7%; Cronos (CRON) -6.5%; Cresco (CRLBF) -6.0%
11 constituents had price changes of less than 5%.
As mentioned in previous articles the pot stock universe has:
- 400+ pure-play and ancillary securities listed on the various Canadian and American stock exchanges,
- 300 or so of the listed securities trade occasionally of which
- 200 actively trade on a regular basis of which only
- 29 stocks trade for at least US$1/share and, as such, are included in my proprietary equally-weighted Non-penny Pot Stock Index of which:
- 2 trade above US$20/share,
- 4 trade between US$10 and US$20/share,
- 4 trade between US$5 and US$10/share and
- 19 trade between US$1 and US$5/share. (The official definition of a “penny” stock is one that trades below US$5/share but, when it comes to pot stocks, that is where 90% of the total universe trades, so the more literal definition of stocks that trade for less than US$1/share is used.) The official definition of a “penny” stock is one that trades below US$5/share but, when it comes to pot stocks, that is where 90% of the total universe trades, so the more literal definition of stocks that trade for less than US$1/share is used.
The market capitalization makeup of the NPSI (calculated by multiplying the number of a company’s shares outstanding by its stock price per share) is as follows:
- Large-Cap (+US$10B): 0
- Mid-Cap (US$2B to US$10B): 3
- Small-Cap (US$300M to US$2B): 10
- Micro-Cap (US$50M to US$300M): 16
The constituents do business in 6 sector categories as follows based on their primary area of focus in the cannabis industry and the constituents within each category are identified below with how each of the categories performed:
- Vertically Integrated “Seed to Sale” Category: -5.0%
- 22 constituents are in this category, namely: ACRGF; ACB; APHA; AVCNF; AYRSF; CCHWF; CGC; CRLBF; CRON; GTBIF; CURLF; CWBHF; JUSHF; OGI; PLNHF; ROMJF; SHWZ; TCNNF; TLRY; TRSSF; VFF; YCBD.
- 8 are Canadian Licensed Producers (LPs) and
- 14 are American Multi-State Operators (MSOs) of which
- 3 specialize in the cultivation, processing and sale of hemp derived CBD
- Extraction Category: +5.4%
- 2 constituents are in this category, namely: NEPT and VLNCF
- both constituents are Canadian Licensed Producers (LPs)
- BioPharma Category: -7.5%
- 2 constituents are in this category, namely: GWPH and XPHYF
- Marijuana-Infused Products Category: -14.7%
- 1 constituent is in this category, namely: NBEV
- Consumption Devices Category: -+10.7%
- 1 constituent is in this category, namely: GNLN
- Real Estate Category: -6.7%
- 1 constituent is in this category, namely: IIPR
A Few Last Words:
- Click the “Like” button at the top of the page if you found this article a worthwhile read as this will help us build a bigger audience.
- Comment below if you want to share your opinion or perspective with other readers and possibly exchange views with them.
- Register to receive our free Market Intelligence Report newsletter (sample here) in the top right hand corner of this page.
- Join us on Facebook to be automatically advised of the latest articles posted and to comment on any of them.
About Lorimer Wilson
Lorimer Wilson is an economic & financial commentator who has written numerous articles on economics, personal finance, the gold, silver and cannabis markets and investing. He is the editor of munKNEE.com a site that provides a selection of the internet’s best finance articles in an edited, reformatted and abridged format to ensure a fast and easy read. He is also a frequent contributor to TalkMarkets.com, eResearch.com, Gold-Eagle.com, MarketOracle.co.uk and 24hGold.com
munKNEE.com has joined eResearch.com to provide you with individual company research articles and specific stock recommendations in addition to munKNEE’s more general informative articles on the economy, the markets, and gold, silver and cannabis investing.
7 major consumer and pharmaceutical corporations have bought into marijuana companies to take full advantage of this rapidly growing market and this article compares their stock performance YTD compared with that of their marijuana partners.
This article highlights the performance of the 12 “momentum” stocks within the Non-penny Pot Stock Index which, given that they represent only 4% of all cannabis stocks, certainly warrant your consideration.
When analyzing the cannabis stock sector it is important to know which companies are doing business within each of the industry’s 11 categories so one can make a meaningful comparison of percentage changes in price performances with their peers. This article demystifies the makeup of the fledgling pot stock market.
At the height of the cannabis stock frenzy back in March/April of 2019 there were 17 companies out of a total of 319 companies listed on the various stock exchanges with valuations over $1 billion but now there are only 7. Here is the list.
Cannabis companies are on the edge of disappearing just as quickly as they appeared due to numerous companies struggling to raise capital while reaching closer and closer towards insolvency.
As a result of the growing level of mainstream interest in the burgeoning marijuana industry the S&P/TSX has recently launched two indices, the S&P/TSX Cannabis Index and the S&P/MX International Cannabis Index.
Even though the cannabis industry has been absolutely destroyed in the past 12 months (-76.8%), the cash crunch that contributed to the sell-off isn’t over. It begs the question: “Who’s next to kick the bankruptcy bucket?”
HEXO today reported its financial results today for the second quarter fiscal 2020 ended January 31, 2020. The results failed to meet analysts’ expectations causing its stock to go into freefall.
As investor interest in the cannabis sector has heated up, more and more companies have raised capital through the public markets in Canada, leading to the existence of hundreds of publicly-traded cannabis stocks – and a relatively new stock exchange. Here are the details.
We think balance sheet and staying power will dictate the competitive landscape in 2020.
Of the total 5100 companies we rank weekly there are only 400 that we consider as viable candidates for investment and, of those, only 16 cannabis stocks generate the data necessary to evaluate them properly – and only these few make the grade.
We think 2020 will be another tough year for the marijuana sector. We see more corporate failures, asset deals, and only a handful of players surviving in the long-term.
Any portfolio manager contemplating investing in the fledgling cannabis industry needs a simple, yet robust, credit model that ranks the top 25 public U.S. cannabis companies to make an informed decision as to which cannabis company warrants investing their clients’ money in and this article provides just that.
When you add up the taxes on dispensaries, growers, sales, and local government taxes, you get a fuller picture of how taxed the cannabis industry actually is.
16 states are likely to vote for marijuana legalization this year and such an influx of fresh demand would breathe life into the distressed industry and result in a big year for the troubled pot stock sector.
State tax revenue is the main reason for legalizing the sale of medical and recreational marijuana. The U.S. cannabis market was worth an $11.3 billion in 2018 – and is expected to reach about $30 billion by 2025. Here’s a look at the latest annual marijuana tax revenue by state where it is legal to sell marijuana.
The post How Well Did Non-penny Pot Stocks Do Last Week? Terribly! Check it Out appeared first on munKNEE.com.
Source: munknee.comFollow us: